Nokia Corporation (ADR) (NYSE:NOK) Oyj (NOK1V)’s raised earnings target failed to convince investors seeking support for a stock that had gained about 25 percent in six months, underlining the challenge faced by Chief Executive Officer Rajeev Suri. Adjusted operating profit at the wireless-network unit, which makes up about 90 percent of Nokia’s sales, is targeted at 8 percent to 11 percent of revenue long term, the Espoo, Finland-based company said on 13 November. Analysts on average predict 10.8 percent for 2015 and 10.6 percent for 2016, according to Nordea Bank AB. Nokia Corporation (ADR) (NYSE:NOK) in last trading activity fell -4.84% to close at $7.86. Company weekly performance is -1.87% while its quarterly performance stands at 0.51%. Nokia Corporation (ADR) (NYSE:NOK) is -9.97% away from its 52 week high.
Zacks downgraded shares of Urban Outfitters (NASDAQ:URBN) from a neutral rating to an underperform rating in a report issued on Wednesday. They currently have $28.00 target price on the stock On last trading day Urban Outfitters Inc. (NASDAQ:URBN) fell -2.53% to close at $30.85. Its volatility for the week is 3.27% while volatility for the month is 2.68%. URBN’s sales growth for past 5 years was 11.00% and its EPS growth for past 5 years was 10.10%. Urban Outfitters Inc. (NASDAQ:URBN) monthly performance is -10.73%.
Amicus Therapeutics (NASDAQ:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, announced additional positive data on important secondary endpoints from its second Phase 3 study (Study 012) of the oral small molecule chaperone migalastat HCl (“migalastat”) for Fabry disease. In a poster1 at the American Society of Nephrology (ASN) Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy (ERT) to migalastat as their only therapy for Fabry disease. On last trading day Amicus Therapeutics, Inc. (NASDAQ:FOLD) fell -3.07% to close at $5.69. Its volatility for the week is 6.61% while volatility for the month is 5.34%. FOLD’s sales growth for past 5 years was -51.60% and its EPS growth for past 5 years was 7.90%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) monthly performance is 0.53%.
TrueCar (NASDAQ:TRUE) CAO John Pierantoni purchased 3,000 shares of TrueCar stock on the open market in a transaction that occurred on Wednesday, November 12th. The stock was purchased at an average cost of $17.00 per share, with a total value of $51,000.00. Following the acquisition, the chief accounting officer now directly owns 14,260 shares in the company, valued at approximately $242,420. TrueCar, Inc. (NASDAQ:TRUE) has 10.50% insider ownership while its institutional ownership stands at 43.00%. In last trading activity company’s stock closed at $17.75.
On Friday shares of United States Brent Oil ETF (NYSE:BNO) closed at $31.34.